United Kingdom Osteoporosis Drugs Market 인사이트
발행일: 09 May 2026 | 보고서 형식: 전자(PDF)
United Kingdom Osteoporosis Drugs Market is growing at an 4.61% CAGR, driven by aging population, rising fractures, improved awareness
United Kingdom Osteoporosis Drugs Market Insights Forecasts to 2035
- The United Kingdom Osteoporosis Drugs Market Size Was Estimated at USD526.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around4.61% from 2025 to 2035
- The United Kingdom Osteoporosis Drugs Market Size is Expected to ReachUSD 826.3Million by 2035
Notable Insights for United Kingdom Osteoporosis Drugs Market
- By drug class, bisphosphonates dominated, accounting for approximately65% share in 2024, while denosumab held20% shareand other therapies collectively accounted for25% share, driven by first-line use and cost-effectiveness in fracture prevention.
- By therapy type, long-term osteoporosis management therapies dominated, holding approximately75% share, whereas acute or short-duration therapies represented30% share, due to rising elderly population and recurrent fracture prevention needs.
- Approximately3 million people in the UK (100% estimated burden)are affected by osteoporosis, with60% prevalence among postmenopausal women,35% among elderly men and women combined, and15% undiagnosed or high-risk cases, reflecting significant disease underdiagnosis.
- Around75% of diagnosed patients receive oral osteoporosis medications, while20% are treated with injectable biologics, and15% receive hormone-based or combination therapies, showing a diversified treatment landscape in clinical practice.
전자책(목차) 다운로드
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Osteoporosis Drugs Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Osteoporosis Drugs Market
- Amgen
- Eli Lilly and Company
- Novartis
- Pfizer
- Teva Pharmaceutical Industries
- Roche
- Viatris
- Theramex
- Others
Recent Developments:
- In June 2024, Barinthus BiotherapeuticsreportedPhase 2 data for VTP-300showing reduced HBsAg levels and potential nucleos(t)ide analogue discontinuation in selected chronic hepatitis B patients supporting therapeutic vaccine development.
- InMarch 2024, Gilead expanded Vemlidy (tenofovir alafenamide)indication for pediatric chronic hepatitis B patients, reinforcing antiviral treatment continuity and supporting long-term hepatitis B management strategies across global markets globally.
Market Segmentation:
United Kingdom Osteoporosis Drugs Market, By Drug Class
- Bisphosphonates
- RANK Ligand Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone Therapies
- Calcitonin
- Others
United Kingdom Osteoporosis Drugs Market, By Route of Administration
- Oral
- Injectable
United Kingdom Osteoporosis Drugs Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Orthopedic Centers
United Kingdom Osteoporosis Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Osteoporosis Drugs Market is expected to grow steadily due to rising aging populations, increasing osteoporosis-related fracture incidence, and expanding NHS bone health initiatives. Experts emphasize that bisphosphonates will remain the leading treatment category because of their established efficacy and affordability. Increasing adoption of biologics, improved diagnostic screening programs, and advancements in targeted osteoporosis therapies are anticipated to strengthen long-term disease management and support market expansion through 2035.